MICHAEL FLANAGAN: Open Payments
NPI 1851453252 · BRYN MAWR, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,219 in 57 payments from 20 companies in 2025. Trend: 2023 $1,154 · 2024 $1,149 · 2025 $1,219
Food & beverage: $1,219
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $148 |
| Novo Nordisk Inc | 5 | $127 |
| Lilly USA, LLC | 6 | $113 |
| AstraZeneca Pharmaceuticals LP | 6 | $102 |
| Lundbeck LLC | 4 | $77 |
| Abbott Laboratories | 3 | $72 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $68 |
| Daiichi Sankyo Inc. | 2 | $58 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Amgen Inc. | 3 | $54 |
Products named: REXULTI, FREESTYLE LIBRE 3, AIRSUPRA, Kerendia, INJECTAFER, UBRELVY, Auvelity, QULIPTA.
Industry payments across PA — which companies pay providers there.
